GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Provectus Biopharmaceuticals PVCT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.05

-5.66%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Provectus Biopharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Provectus Biopharmaceuticals is based in Knoxville, Tennessee and is incorporated in Delaware. Its shares trade on OTC under the ticker PVCT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $336,108 and a net loss of $5.4m. At that date it held total assets of $697,502 and shareholders' equity of −$6.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Apr 2000
Employees
4
Head office
800 S. GAY STREET, KNOXVILLE, TN, 37929
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Edward PershingExecutive Chairman of the Board, Chief Executive Officer, since 2018$2.2m
  • Mr. Dominic RodriguesExecutive Vice Chairman of the Board, President, Principal Executive Officer, since 2017$1.5m
  • Mrs. Heather RainesChief Financial Officer$125,000
  • Dr. Eric WachterChief Technology Officer, since 2002$399,752
  • Mr. Webster BaileyIndependent Director$80,000
  • Dr. John LaceyIndependent Director$80,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Provectus Biopharmaceuticals focuses on innovative immunotherapy medicines based on halogenated xanthenes for oncology and dermatology.
  • The company's lead molecule rose bengal sodium (RBS) is part of a versatile platform for multiple disease areas.
  • Provectus has a small molecule HX platform with clinical programs in oncology, dermatology, and ophthalmology.

Weaknesses

  • The company employs only four full-time employees, limiting operational capacity.
  • Provectus has no commercialized products, relying solely on development stage research.
  • The firm's IPO in 2000 has not led to significant market presence or revenue.

Opportunities

  • The HX platform offers potential for new drug candidates in oncology, hematology, and wound healing.
  • Expanding clinical programs in dermatology and ophthalmology could attract new partnerships.
  • Provectus can leverage its small molecule platform for additional indications like infectious diseases.

Threats

  • The development stage nature of the company poses high financial risk without revenue streams.
  • Competition in oncology and dermatology markets is intense with established players.
  • Regulatory hurdles may delay clinical trials and product approvals for HX-based therapies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.